Zevra Therapeutics (ZVRA) Equity Ratio: 2014-2025
Historic Equity Ratio for Zevra Therapeutics (ZVRA) over the last 10 years, with Sep 2025 value amounting to 0.49.
- Zevra Therapeutics' Equity Ratio rose 35.35% to 0.49 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.49, marking a year-over-year increase of 35.35%. This contributed to the annual value of 0.22 for FY2024, which is 37.97% down from last year.
- Zevra Therapeutics' Equity Ratio amounted to 0.49 in Q3 2025, which was up 7.77% from 0.46 recorded in Q2 2025.
- Zevra Therapeutics' Equity Ratio's 5-year high stood at 4.17 during Q2 2023, with a 5-year trough of 0.22 in Q4 2024.
- Moreover, its 3-year median value for Equity Ratio was 0.36 (2024), whereas its average is 1.04.
- In the last 5 years, Zevra Therapeutics' Equity Ratio soared by 279.04% in 2022 and then plummeted by 94.60% in 2024.
- Over the past 5 years, Zevra Therapeutics' Equity Ratio (Quarterly) stood at 0.96 in 2021, then crashed by 31.89% to 0.65 in 2022, then tumbled by 44.88% to 0.36 in 2023, then plummeted by 37.97% to 0.22 in 2024, then surged by 35.35% to 0.49 in 2025.
- Its Equity Ratio stands at 0.49 for Q3 2025, versus 0.46 for Q2 2025 and 0.24 for Q1 2025.